Matches in SemOpenAlex for { <https://semopenalex.org/work/W605169669> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W605169669 endingPage "736" @default.
- W605169669 startingPage "736" @default.
- W605169669 abstract "736 Background: Dose-dense chemotherapy may achieve superior clinical outcomes over conventionally administered chemotherapy in BC. The primary objective of this study was to evaluate the RR of biweekly T plus E in LABC (stage III). Secondary objectives were to determine pathological response rate, safety profile and the correlation between the expression of molecular markers (MM) and response. Methods: Patients with histologically or cytologically confirmed LABC, age ≥ 18 years, ECOG PS ≤ 2 and adequate bone marrow, hepatic, renal and cardiac functions were eligible. Prior chemotherapy, hormonal therapy or radiotherapy was not allowed. Patients with invasive bilateral BC were excluded. Treatment: E (75 mg/m2) and T (75 mg/m2) iv, every 14 days with G-CSF support for 6 cycles. Surgery was recommended 3–6 weeks after completion of chemotherapy. The expression of MM, such as ER, PR, HER-2 was assessed and correlated with clinical and pathological responses. Results: To date, 48 patients have been included. Median age was 51 (31–77), 98% had ECOG PS 0–1, tumor stage IIIA (41%) and IIIB (59%). MM expression was determined (ER+ 58%, PR+ 48%, HER-2+ 53%). A total of 262 cycles (median 6, range 1–6) was administered. Median RDI was 97% and 98% for T and E, respectively. All patients were evaluable for toxicity. Main grade 3/4 toxicities per patient were neutropenia (9%), leukopenia (9%), anaemia (4%). Febrile neutropenia was observed in 2 patients, 1 cycle each. Efficacy: Eight patients were not evaluable (1 missed evaluation, 3 dropped-out without evaluation and 4 still ongoing). Of 40 patients, 7 achieved CR (18%), 22 PR and 11 SD resulting in an ORR of 73% (95% CI: 59–86). Surgery was performed in 39 patients and 8% had complete pathological response. Logistic regression analysis suggested that neither hormone receptor status nor HER-2 status correlated with clinical response. Conclusions: Biweekly T plus E is an active and well-tolerated neoadjuvant regimen for patients with LABC and high expression of HER-2 (53%). No significant financial relationships to disclose." @default.
- W605169669 created "2016-06-24" @default.
- W605169669 creator A5022227093 @default.
- W605169669 creator A5037091106 @default.
- W605169669 creator A5040401399 @default.
- W605169669 creator A5041043875 @default.
- W605169669 creator A5043967749 @default.
- W605169669 creator A5048494721 @default.
- W605169669 creator A5056905941 @default.
- W605169669 creator A5061487896 @default.
- W605169669 creator A5072353911 @default.
- W605169669 creator A5089627406 @default.
- W605169669 date "2004-07-15" @default.
- W605169669 modified "2023-10-16" @default.
- W605169669 title "Dose-dense neoadjuvant treatment with biweekly docetaxel (T) plus epirubicin (E) for locally advanced breast cancer (LABC). An ONCOPAZ Cooperative Group Study" @default.
- W605169669 doi "https://doi.org/10.1200/jco.2004.22.90140.736" @default.
- W605169669 hasPublicationYear "2004" @default.
- W605169669 type Work @default.
- W605169669 sameAs 605169669 @default.
- W605169669 citedByCount "0" @default.
- W605169669 crossrefType "journal-article" @default.
- W605169669 hasAuthorship W605169669A5022227093 @default.
- W605169669 hasAuthorship W605169669A5037091106 @default.
- W605169669 hasAuthorship W605169669A5040401399 @default.
- W605169669 hasAuthorship W605169669A5041043875 @default.
- W605169669 hasAuthorship W605169669A5043967749 @default.
- W605169669 hasAuthorship W605169669A5048494721 @default.
- W605169669 hasAuthorship W605169669A5056905941 @default.
- W605169669 hasAuthorship W605169669A5061487896 @default.
- W605169669 hasAuthorship W605169669A5072353911 @default.
- W605169669 hasAuthorship W605169669A5089627406 @default.
- W605169669 hasConcept C121608353 @default.
- W605169669 hasConcept C126322002 @default.
- W605169669 hasConcept C126894567 @default.
- W605169669 hasConcept C141071460 @default.
- W605169669 hasConcept C143998085 @default.
- W605169669 hasConcept C2776694085 @default.
- W605169669 hasConcept C2776907518 @default.
- W605169669 hasConcept C2777063308 @default.
- W605169669 hasConcept C2778850193 @default.
- W605169669 hasConcept C2780835546 @default.
- W605169669 hasConcept C2780873365 @default.
- W605169669 hasConcept C2781190966 @default.
- W605169669 hasConcept C530470458 @default.
- W605169669 hasConcept C71924100 @default.
- W605169669 hasConcept C90924648 @default.
- W605169669 hasConceptScore W605169669C121608353 @default.
- W605169669 hasConceptScore W605169669C126322002 @default.
- W605169669 hasConceptScore W605169669C126894567 @default.
- W605169669 hasConceptScore W605169669C141071460 @default.
- W605169669 hasConceptScore W605169669C143998085 @default.
- W605169669 hasConceptScore W605169669C2776694085 @default.
- W605169669 hasConceptScore W605169669C2776907518 @default.
- W605169669 hasConceptScore W605169669C2777063308 @default.
- W605169669 hasConceptScore W605169669C2778850193 @default.
- W605169669 hasConceptScore W605169669C2780835546 @default.
- W605169669 hasConceptScore W605169669C2780873365 @default.
- W605169669 hasConceptScore W605169669C2781190966 @default.
- W605169669 hasConceptScore W605169669C530470458 @default.
- W605169669 hasConceptScore W605169669C71924100 @default.
- W605169669 hasConceptScore W605169669C90924648 @default.
- W605169669 hasIssue "14_suppl" @default.
- W605169669 hasLocation W6051696691 @default.
- W605169669 hasOpenAccess W605169669 @default.
- W605169669 hasPrimaryLocation W6051696691 @default.
- W605169669 hasRelatedWork W164949807 @default.
- W605169669 hasRelatedWork W1982206062 @default.
- W605169669 hasRelatedWork W2056584284 @default.
- W605169669 hasRelatedWork W2074378511 @default.
- W605169669 hasRelatedWork W2092226662 @default.
- W605169669 hasRelatedWork W2093981422 @default.
- W605169669 hasRelatedWork W2106964779 @default.
- W605169669 hasRelatedWork W2240515971 @default.
- W605169669 hasRelatedWork W2977409384 @default.
- W605169669 hasRelatedWork W2999074841 @default.
- W605169669 hasVolume "22" @default.
- W605169669 isParatext "false" @default.
- W605169669 isRetracted "false" @default.
- W605169669 magId "605169669" @default.
- W605169669 workType "article" @default.